Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis

Only limited therapeutic agents have been developed for non-alcoholic steatohepatitis (NASH). Glabridin, a promising anti-obesity candidate, has only limited druggability due to its low in vivo chemical stability and bioavailability. Therefore, we developed vutiglabridin (VUTI), which is based on a glabridin backbone, and investigated its mechanism of action in treating NASH in animal models.